Open Access. Powered by Scholars. Published by Universities.®
Bilingual, Multilingual, and Multicultural Education Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Bilingual, Multilingual, and Multicultural Education
Leptin Induces Proliferation And Notch Expression In Pancreatic Cancer, Felice Watson, Ruben Gonzalez-Perez, Phd
Leptin Induces Proliferation And Notch Expression In Pancreatic Cancer, Felice Watson, Ruben Gonzalez-Perez, Phd
Journal of Health Disparities Research and Practice
Pancreatic adenocarcinoma (PA) is an aggressive cancer. It develops in a way that causes almost no detectable symptoms, which leads to a rapid progression and a short survival rate.
Researchers have discovered a link between pancreatic cancer (and other cancer types) and obesity. High levels of leptin, an appetite hormone secreted by adipocytes, have been found in obese people. Studies have shown that the absence of leptin in the body or severe leptin resistance can lead to uncontrolled eating and weight gain, hence, its connection to obesity. Consequently, our lab is analyzing the relationship between obesity and leptin and what …
Exploration Of Antagonist Efficacy For Lpra2 Like Peptide, Ayobami Loye, Ruben R. Gonzalez-Perez, Phd
Exploration Of Antagonist Efficacy For Lpra2 Like Peptide, Ayobami Loye, Ruben R. Gonzalez-Perez, Phd
Journal of Health Disparities Research and Practice
Leptin is a small protein hormone that controls satiety and is produced by adipocytes. Obese people have increased levels of circulating leptin. Excessive leptin levels cause a break down in the control of leptin signaling pathways leading to increased angiogenesis, proliferation, cell migration, invasion, and anti-apoptotic events. Obesity and leptin signaling have been linked to cancer progression. Literature shows that LPrA2 is an effective leptin antagonist as it decreases proliferation of breast cancer cells in vitro.
This project compares the effectiveness of LPrA2 like compounds in breast cancer cell-line MDA-MB-468 (M-468 BCs). We hypothesize that the new peptide antagonists have …